{"version":"1.0","type":"link","title":"CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma: lessons learned from clinical trials and real world evidence.","author_name":"Gupta S 외","author_url":"https://prs-insight.online/author/Gupta%20S","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/165366","thumbnail_width":1200,"thumbnail_height":630}